Liver alterations in antituberculosis regimens containing pyrazinamide

Area of Science:

• Hepatology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) treatment in alcoholic patients presents challenges due to potential co-existing liver damage.
• Pyrazinamide is a crucial component of TB regimens, but its hepatotoxicity is a concern, especially in vulnerable populations.

Purpose of the Study:

• To evaluate the safety and efficacy of pyrazinamide-containing regimens in alcoholic patients with tuberculosis.
• To assess the impact of chemotherapy on liver function in this patient group.

Main Methods:

• A prospective study involving alcoholic tuberculous patients treated with a pyrazinamide-containing regimen (IRSZ).
• Liver histology and function tests were assessed at baseline and after two months of treatment.
• A control group received a non-pyrazinamide regimen (IRSE), and a separate group received pyrazinamide (Z) alone.

Main Results:

• Significant improvements in liver histology and function tests were observed after two months of pyrazinamide-containing chemotherapy.
• Both pyrazinamide-containing and control regimens demonstrated good liver tolerance.
• Pyrazinamide monotherapy also showed excellent liver tolerance in nonalcoholic patients.

Conclusions:

• Pyrazinamide-containing regimens are well-tolerated in tuberculous alcoholic patients, provided there is no significant pre-existing hepatic dysfunction.
• Careful monitoring of liver function, including SGPT and bilirubin levels, is recommended during treatment.